Elucidation of the Effects of Growth Hormone (GH) Deficiency and GH Replacement on Clot and Platelet

The Leeds Teaching Hospitals NHS Trust

Status: Unknown

Conditions: Hypopituitary Adults

Treatments: Drug: Growth Hormone Therapy

Study type: Observational

Funder types: Other

Identifiers

NCT02049671

ED12/10391

13/YH/0061 (Other Identifier)

Details and patient eligibility

About

Large population studies of hypopituitary adults (patients with pituitary gland failure) on conventional hormone replacement, but not growth hormone, have an approximate two fold increase in death rate (mortality). The vast majority of this excess mortality relates to vascular disease. While it is possible that overreplacement with steroids, underreplacement with thyroid hormones and sex hormone deficiency contribute, there are increasing data to support a role for GH in the cause of the excess vascular risk. Although a number of surrogates of vascular risk are described in patients with GH deficiency (GHD), how these translate mechanistically into atherothrombotic (blockage of the arteries) disease has not been fully elucidated.

This proposed study will analyse both traditional (body composition, serum lipids, handling of sugars)and more complex markers (inflammation, procoagulation, fibrinolysis) of vascular risk/disease. In addition the study will examine 24hr blood pressure, arterial wall thickness, clot structure and function, as well as platelet action. Measurements will be performed at baseline and will be reassessed after patients have been on a stable dose of GH replacement for at least three months.

The results of the study will characterise risk factors for vascular disease, and take this a step further to elucidate how these changes translate mechanistically in to vascular damage.

Enrollment: 150 estimated patients

Sex: All

Ages: 16 to 90 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Able to give written consent
• Adults with confirmed GHD (Insulin stimulation test <3ug/L)
• Other hormone replacement therapy stable for at least three months

Exclusion criteria

• active malignancy
• an acute vascular event within three months of the study
• any therapy other than hormone replacement
• serum creatinine >120 micromol/l
• abnormal LFTs (ALT>3 fold upper limit of normal)

Trial design

150 participants in 2 patient groups

Growth Hormone Therapy

Treatment:

Drug: Growth Hormone Therapy

Control Group